🇺🇸 Comirnaty in United States

Comirnaty (BNT162b2 (tozinameran)) regulatory status in United States.

Marketing authorisation

FDA

  • Status: approved

Pricing & reimbursement

Comirnaty in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Infectious Disease approved in United States

Frequently asked questions

Is Comirnaty approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Comirnaty in United States?

Pfizer Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.

What does Comirnaty cost in United States?

annual_list: USD 3400.00 per year. Final patient cost depends on reimbursement and any patient access scheme.